Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is well-positioned to succeed given the promising data from their current Phase 2 SimpliciT1 trial and the upcoming completion of enrollment in their Phase 3 CATT1 trial. Additionally, the company has a diverse pipeline of other candidates in development, providing upside potential. With a strong cash position and potential for additional financing, vTv Therapeutics is poised for success in a competitive market.

Bears say

vTv Therapeutics is facing challenges in gaining widespread adoption of its lead candidate, cadisegliatin, with only slight increases in projected penetration rates for hypoglycemia-burdened T1D patients. Despite enthusiasm from pediatric clinicians, the unpredictable needs and persistent challenges faced by adolescent T1D patients may limit the drug's potential impact. Furthermore, with a projected peak sales of only $840 million, the company's financial outlook may also be impacted by limited market penetration.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of Aug 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.